The 2025-2026 SARS-CoV-2 vaccines provided protection against ED/UC visits and hospitalizations among immunocompetent adults.

MRNA surged 14%, dwarfing the 2% gains of MRK and PFE, driven by an FDA flu vaccine endorsement and a blowout Q1 revenue beat. Despite MRNA's 130% YTD surge, Wall Street's consensus target of $43 sits ...

Moderna is aggressively trying to replace lost COVID-19 vaccine revenue by moving into multivalent and seasonal respiratory markets. The immediate catalyst is mFlusiva, Moderna's investigational ...

Shares of Moderna (NASDAQ: MRNA) jumped during the COVID-19 pandemic, but when its COVID-19 vaccine revenue dried up, the stock slumped. However, the company has recently shown it isn't a one-trick ...

German health minister Karl Lauterbach (R) gets a vaccination against Influenza and Covid-19 by army doctor Nicole Mueller at the Bundeswehr hospital in Berlin, Germany, on October 16, 2024. Ebrahim ...

WASHINGTON (AP) — A new kind of flu vaccine moved a step closer to the U.S. market Thursday as federal health advisers recommended approval of the first made with the same mRNA technology that was key ...

A Food and Drug Administration advisory committee voted that the benefits of a seasonal flu vaccine from Moderna MRNA-10.83%decrease; down pointing triangle outweigh its risks, part of the agency’s ...

Moderna Inc.’s influenza vaccine made with mRNA technology was recommended for approval by outside advisers to the US Food and Drug Administration, a positive development for what has been a ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. A sign marks an entrance to a Moderna building in ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. A panel of advisers to the Food and Drug ...

As Moderna reshapes itself in the wake of the pandemic, the company on Thursday passed a key milestone in its bid to expand the reach of its mRNA platform to the massive influenza vaccination market.